NEULASTAHCP.COM: Keyword Density Checker

Total words: 5626 | 2-word phrases: 1443 | 3-word phrases: 1693 | 4-word phrases: 1805

PAGE INFO

Title	Try to keep the title under 60 characters (74 characters) Febrile Neutropenia Reduction \| Neulasta® (pegfilgrastim) Onpro®
Description	Try to keep the meta description between 50 - 160 characters (0 characters)
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (72 characters) The #1 prescribed long-acting G-CSF1,*, used in over 1 million patients2

#	Keyword	Frequency	Density
1	data on file	19	1.12%
2	on file amgen	18	1.06%
3	instructions for use	15	0.89%
4	file amgen 2	13	0.77%
5	in patients with	9	0.53%
6	in patients receiving	8	0.47%
7	onbody injector obi	8	0.47%
8	references 1 data	7	0.41%
9	1 data on	7	0.41%
10	the obi to	6	0.35%
11	for manual use	6	0.35%
12	syringe for manual	6	0.35%
13	with the obi	6	0.35%
14	reported in patients	6	0.35%
15	serious allergic reactions	6	0.35%
16	patients receiving neulasta®	6	0.35%
17	to the patient	6	0.35%
18	2 data on	5	0.30%
19	file amgen 1	5	0.30%
20	et al j	5	0.30%
21	has been reported	5	0.30%
22	patients with breast	5	0.30%
23	in patients who	4	0.24%
24	to the patient’s	4	0.24%
25	blood cell count	4	0.24%
26	discontinue neulasta® in	4	0.24%
27	the patient’s skin	4	0.24%
28	patients who develop	4	0.24%
29	a healthcare provider	4	0.24%
30	they suspect that	4	0.24%

#	Keyword	Frequency	Density
1	data on file amgen	18	1.00%
2	on file amgen 2	12	0.66%
3	references 1 data on	7	0.39%
4	syringe for manual use	6	0.33%
5	1 data on file	6	0.33%
6	on file amgen 1	5	0.28%
7	2 data on file	5	0.28%
8	in patients receiving neulasta®	5	0.28%
9	if they suspect that	4	0.22%
10	to determine the need	4	0.22%
11	they suspect that the	4	0.22%
12	suspect that the device	4	0.22%
13	been reported in patients	4	0.22%
14	white blood cell count	4	0.22%
15	injector obi for neulasta®	4	0.22%
16	to the patient’s skin	4	0.22%
17	patient instructions for use	4	0.22%
18	determine the need for	4	0.22%
19	order to determine the	4	0.22%
20	in order to determine	4	0.22%
21	with breast and lung	4	0.22%
22	neulasta® injection 6 mg06	4	0.22%
23	missed or partial dose	4	0.22%
24	injection 6 mg06 ml	4	0.22%
25	6 mg06 ml in	4	0.22%
26	mg06 ml in a	4	0.22%
27	patients with sickle cell	4	0.22%
28	patients with breast and	4	0.22%
29	prefilled syringe for manual	4	0.22%
30	has occurred in patients	4	0.22%
31	professional immediately in order	4	0.22%
32	immediately in order to	4	0.22%
33	treatment plans on track	3	0.17%
34	in patients with breast	3	0.17%
35	has been reported in	3	0.17%
36	in patients with a	3	0.17%
37	healthcare professional immediately in	3	0.17%
38	hcp instructions for use	3	0.17%
39	not performing as intended	3	0.17%
40	breast and lung cancer	3	0.17%

#	URL	Whois	Check
1	https://www.pi.amgen.com/united_states/neulasta/neulasta_patient_ifu_obi.pdf	Whois	amgen.com
2	https://www.pi.amgen.com/united_states/neulasta/neulasta_hcp_ifu_obi.pdf	Whois	amgen.com
3	https://www.pi.amgen.com/united_states/neulasta/neulasta_pfs_ifu.pdf	Whois	amgen.com
4	https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Neulasta/neulasta_pi_hcp_english.pdf	Whois	amgen.com
5	https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Neulasta/neulasta_pi_hcp_english.pdf	Whois	amgen.com
6	http://wwwext.amgen.com/	Whois	amgen.com